Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
08:00pm, Tuesday, 06'th May 2025
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare wit
Halozyme Therapeutics, Inc. (HALO) Q1 2025 Earnings Call Transcript
07:15pm, Tuesday, 06'th May 2025
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations & Corporate Communications Helen T
Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates
06:35pm, Tuesday, 06'th May 2025
Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.11 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of $0.79 per share a year ago.
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS
04:01pm, Tuesday, 06'th May 2025
Announcing New $250M Share Repurchase Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million; Adjusted EBI
Halozyme to Participate in the BofA Securities 2025 Healthcare Conference
05:15pm, Monday, 05'th May 2025
SAN DIEGO , May 5, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host inve
Halozyme Therapeutics: Still Undervalued Ahead Of Earnings
09:06am, Thursday, 01'st May 2025
Halozyme Therapeutics, Inc. remains a buy due to its strong subscription-based business model, high growth, and undervaluation. HALO's robust product library, focused on drug delivery systems, positio
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
11:06am, Tuesday, 29'th Apr 2025
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Halozyme to Report First Quarter 2025 Financial and Operating Results
08:30am, Monday, 28'th Apr 2025
SAN DIEGO , April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2025 financial and operating results on Tuesday, M
European Commission (EC) decision on marketing authorization application expected within approximately two months SAN DIEGO , April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO)
Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation
08:30am, Thursday, 24'th Apr 2025
Complaint filed in New Jersey alleges Merck uses Halozyme's patented MDASE technology to develop SC Keytruda Halozyme is seeking damages and injunctive relief to stop the infringement SAN DIEGO , Apr
AI-Powered Platform Now Fully Operational to Support Data Capture, Remote Monitoring, and Virtual Treatment with HALO™ AI-Powered Platform Now Fully Operational to Support Data Capture, Remote Monit
Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market
04:09pm, Friday, 11'th Apr 2025
Shares of biotech stock Halozyme found support at their 200-day line in a time where many stocks are below this level. The post Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatil
SAN DIEGO , April 10, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx has received U.S. Food and Drug Administration (FDA) approval of VYVGART®
Subcutaneous DARZALEX® is co-formulated with Halozyme's ENHANZE® drug delivery technology SAN DIEGO , April 9, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announ
SAN DIEGO , April 7, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, has received European
